US Patent

US11413360 — Dual mode radiotracer andâtherapeutics

Method of Use · Assigned to Technische Universitaet Muenchen Klinikum Rechts Der Isar · Expires 2038-11-22 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a ligand-SIFA-chelator conjugate, a single molecule with three separate moieties for binding to a disease-relevant target and chelating a cation.

USPTO Abstract

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties: (a) one or more ligands which are capable of binding to a disease-relevant target molecule, (b) a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Drugs covered by this patent

Posluma (FLOTUFOLASTAT F-18 GALLIUM) · Blue Earth

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3614`	—	Posluma

Patent Metadata

Patent number: US11413360
Jurisdiction: US
Classification: Method of Use
Expires: 2038-11-22
Drug substance claim: Yes
Drug product claim: No
Assignee: Technische Universitaet Muenchen Klinikum Rechts Der Isar
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.